Venus Remedies gains on taking its flagship product ‘Elores’ into Latin America

29 Oct 2013 Evaluate

Venus Remedies is currently trading at Rs 193.45, up by 3.05 points or 1.60% from its previous closing of Rs 190.40 on the BSE.

The scrip opened at Rs 193.90 and has touched a high and low of Rs 193.90 and Rs 193.45 respectively.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 358.05 on 15-May-2013 and a 52 week low of Rs 140.00 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs 202.00 and Rs 170.80 respectively. The current market cap of the company is Rs 221.00 crore.

The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 9.95% and 46.06% respectively.

Venus Remedies has made inroads into Latin America by securing the first marketing authorization for its patent-protected novel antibiotic adjuvant entity ‘Elores’ from Guatemala. This will enable them to expand its research product portfolio in Latin American country and the company will launch the product in early 2014.

Cashing in on this tremendous opportunity, the company expects to generate revenue of $5 million within three years of the launch. Keeping the rapid emergence of resistant microbes in mind, Elores is the need of the hour in Latin American countries at this juncture. Ever since the company launched Elores in the Indian markets in January this year, the product had been receiving a tremendous response from the medical fraternity across the nation.

Elores, the flagship product of Venus Remedies, is known for its efficacy against serious multidrug-resistant hospital-acquired infections involving metallo-beta-lactamase and carbapenem-resistant strains of bacteria such as E. coli, K. pneumoniae, P. aeruginosa and A. baumanni. Elores has a unique profile of action, which gives it an edge over all the existing therapies. The product has recorded a significant reduction in treatment time and cost by up to 30%. It prevents both development and spread of bacterial resistance from one species to another, which makes it one of the safest drugs available to cater to multidrug-resistant carbapenem-resistant enterobacteriaceae (CREs).

Venus Remedies Share Price

745.20 -7.70 (-1.02%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×